DK3558335T3 - Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions - Google Patents
Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions Download PDFInfo
- Publication number
- DK3558335T3 DK3558335T3 DK17883876.9T DK17883876T DK3558335T3 DK 3558335 T3 DK3558335 T3 DK 3558335T3 DK 17883876 T DK17883876 T DK 17883876T DK 3558335 T3 DK3558335 T3 DK 3558335T3
- Authority
- DK
- Denmark
- Prior art keywords
- caspase
- inhibition
- prevention
- treatment
- neurological conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438529P | 2016-12-23 | 2016-12-23 | |
| US201762579936P | 2017-11-01 | 2017-11-01 | |
| PCT/CA2017/051548 WO2018112626A1 (en) | 2016-12-23 | 2017-12-20 | Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3558335T3 true DK3558335T3 (da) | 2023-07-24 |
Family
ID=62624456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17883876.9T DK3558335T3 (da) | 2016-12-23 | 2017-12-20 | Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11160788B2 (da) |
| EP (1) | EP3558335B1 (da) |
| JP (1) | JP7213555B2 (da) |
| KR (1) | KR102590456B1 (da) |
| CN (1) | CN110545835A (da) |
| AU (1) | AU2017383127B2 (da) |
| CA (1) | CA3047836C (da) |
| DK (1) | DK3558335T3 (da) |
| ES (1) | ES2950100T3 (da) |
| FI (1) | FI3558335T3 (da) |
| PL (1) | PL3558335T3 (da) |
| PT (1) | PT3558335T (da) |
| WO (1) | WO2018112626A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022021827A2 (pt) | 2020-05-01 | 2023-01-17 | Medstar Health Inc | Métodos para tratar covid-19 |
| US11952365B2 (en) | 2020-06-10 | 2024-04-09 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| IL309732A (en) | 2021-07-09 | 2024-02-01 | Aligos Therapeutics Inc | Antiviral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| WO2024097731A2 (en) * | 2022-11-02 | 2024-05-10 | Medstar Health, Inc. | Methods for treating covid-19 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302281B6 (cs) | 1998-03-19 | 2011-01-26 | Vertex Pharmaceuticals Incorporated | Inhibitory kaspázy a farmaceutická kompozice, která je obsahuje |
| ATE472539T1 (de) | 2000-04-24 | 2010-07-15 | Vertex Pharma | Verfahren und zwischenprodukte zur herstellung von substituierten asparaginsäure-acetalen |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| KR100538780B1 (ko) | 2002-09-10 | 2005-12-23 | 주식회사 브레인트로피아 | 미노사이클린을 유효성분으로 함유하는 치매 및 기억력감퇴의 예방 및 치료용 조성물 |
| EP1725548B1 (en) | 2004-03-12 | 2015-01-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
| US7531570B2 (en) | 2004-05-27 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Treatment of diseases using ICE inhibitors |
| BRPI0907916A2 (pt) | 2008-02-07 | 2015-07-28 | Boehringer Ingelheim Int | Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos |
| US9365612B2 (en) | 2010-01-29 | 2016-06-14 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Caspase inhibitors |
| EP2635907A4 (en) | 2010-11-05 | 2014-04-16 | Univ Brandeis | ALPHA-SYNUCLEINE CLIVED ICE AS A BIOLOGICAL MARKER |
| ES2907620T3 (es) | 2011-07-18 | 2022-04-25 | Univ Kentucky Res Found | Protección de células de la degeneración inducida por ARN Alu e inhibidores para proteger células |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
-
2017
- 2017-12-20 JP JP2019555521A patent/JP7213555B2/ja active Active
- 2017-12-20 FI FIEP17883876.9T patent/FI3558335T3/fi active
- 2017-12-20 WO PCT/CA2017/051548 patent/WO2018112626A1/en unknown
- 2017-12-20 US US16/471,047 patent/US11160788B2/en active Active
- 2017-12-20 ES ES17883876T patent/ES2950100T3/es active Active
- 2017-12-20 KR KR1020197021496A patent/KR102590456B1/ko active IP Right Grant
- 2017-12-20 DK DK17883876.9T patent/DK3558335T3/da active
- 2017-12-20 CN CN201780084390.7A patent/CN110545835A/zh active Pending
- 2017-12-20 EP EP17883876.9A patent/EP3558335B1/en active Active
- 2017-12-20 PT PT178838769T patent/PT3558335T/pt unknown
- 2017-12-20 AU AU2017383127A patent/AU2017383127B2/en active Active
- 2017-12-20 PL PL17883876.9T patent/PL3558335T3/pl unknown
- 2017-12-20 CA CA3047836A patent/CA3047836C/en active Active
-
2021
- 2021-09-30 US US17/449,526 patent/US20220054454A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP7213555B2 (ja) | 2023-01-27 |
| CA3047836C (en) | 2024-02-06 |
| EP3558335A1 (en) | 2019-10-30 |
| KR20190099497A (ko) | 2019-08-27 |
| CA3047836A1 (en) | 2018-06-28 |
| FI3558335T3 (fi) | 2023-07-19 |
| EP3558335A4 (en) | 2020-09-09 |
| JP2020502282A (ja) | 2020-01-23 |
| ES2950100T3 (es) | 2023-10-05 |
| AU2017383127B2 (en) | 2024-08-15 |
| CN110545835A (zh) | 2019-12-06 |
| KR102590456B1 (ko) | 2023-10-17 |
| US11160788B2 (en) | 2021-11-02 |
| WO2018112626A1 (en) | 2018-06-28 |
| AU2017383127A1 (en) | 2019-07-11 |
| EP3558335B1 (en) | 2023-04-19 |
| US20190328709A1 (en) | 2019-10-31 |
| US20220054454A1 (en) | 2022-02-24 |
| PT3558335T (pt) | 2023-07-20 |
| PL3558335T3 (pl) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266273A (en) | Systems and methods for treating excess fluids | |
| IL298689B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| GB2547402B (en) | Prevention and treatment of microbial infections | |
| DK3558335T3 (da) | Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions | |
| ZA201901055B (en) | Treatment and prevention of sleep disorders | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| ZA202000558B (en) | Prevention and/or treatment of neurodegenerative disease | |
| PL3183003T3 (pl) | SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA | |
| HUE062859T2 (hu) | Szennyvíz kezelése | |
| EP3723742C0 (fr) | Utilisation de la fluoroethylnormemantine pour la prevention et le traitement de l'anxiete | |
| HK1243961A1 (zh) | 炎性病况的預防和治療 | |
| EP3377062C0 (en) | AMINONAPHHOQUINONE COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES | |
| GB201615298D0 (en) | Treatment and prevention of Malaria | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| EP3893861C0 (en) | TREATMENT AND PREVENTION OF GLIOBLASTOMA | |
| GB201719969D0 (en) | Prevention and/or treatment of neurodegenerative disease | |
| GB201815000D0 (en) | Treatment of hypothroidism and related conditions | |
| GB201522828D0 (en) | Prevention and treatment of glaucoma | |
| ITUB20160141A1 (it) | Composizione per la prevenzione ed il trattamento di cefalee primarie | |
| GB201519483D0 (en) | Prevention and treatment of microbial infections | |
| GB201518252D0 (en) | Prevention and treatment of microbial infections | |
| GB201513047D0 (en) | Prevention and treatment of microbial infections | |
| GB201511576D0 (en) | Prevention and treatment of microbial infections | |
| GB201509654D0 (en) | Prevention and treatment of microbial infections |